Weekly Recap | August - W2
Watchlist & Buying Prices Update, Quiet Macro, (Over)Performance & Portfolios Review, Transmedics Trials Approval, Novo's Lawsuits, Earning Review & Weekly Planning.
I joined FiscalAI affiliate program this week and will regularly share my referal link for you guys to have a 15% reduction on all subscription plans.
https://fiscal.ai/?via=wealthyreadings
FiscalAI is the tool I use on my write-ups for any KPIs & honestly the best platform on the market to follow companies. So if ever you’re interested, feel free to use my link!
Weekly Buying List Update.
Here is my watchlist & buying plan. Reaching those prices does not mean I always pull the trigger; those are only my view of valuation & price action today. I only pull the triggers on the ones I believe to be the best liquidity attribution at the moment - purchases are shared on my Savvy B&H portfolio.
https://savvytrader.com/wealthyreadingspro/buyandhodl
Optimized Cost Basis (OCB) - optimum average price for a long term position.
Accumulation Target - buying target based on price action, to average up.
Rating - Buy < 3.5 < Hold < 7 < Trim.
“(Slow) DCA” - trading at proper conditions to open a position or accumulate.
Bold cells are updates compared to last week.
Macro.
There isn’t much to say today as the week was quiet, despite the usual tariffs dance.
Some reciprocal tariffs are now in effect, and I already explained last week why we do not see inflation yet. Adding new tariffs or growing actual ones will of course create more pressure in time, although in this case some were expanded, others reduced.
The new game is played on chips as Trump announced that he would impose a 100% tariff on any chips imported to the U.S. with an exemption for… Nvidia, TSM & some other massive companies which represent 99% of imports - the number isn’t accurate, it is only to illustrate that this practically won’t impact tech companies nor the chip market, and will only impact very small companies who didn’t ask anything of anyone but to scale their business.
So once again… Useless, but the market now knows that most of this is.
Watched Stocks and Portfolio.
Portfolio Review.
As the week is light in terms of news, I thought we could do a portfolio review and talk a bit about my objective for the rest of the year. Here’s a table to summarize, before I share some words for each.
The B&H portfolio was opened in March and is a DCA portfolio with monthy liquidity injection, the Swing portfolio was opened in May and has a fixed liquidity and the option portfolio’s performance is YTD with again a fixed liquidity.
Pretty satisfied with the performance so far, I have made some mistakes & will correct those for the coming months & years. The market is a place of constant learning; what matters is to accept being wrong, to see what we did wrong, and to not reproduce the mistakes.
The B&H portfolio is still ahead of the S&P500 with around 15% of outperformance since March.
I have been building cash this week as we had a nice bounce on the S&P500, but my bias remains bearish short-term with a continual extension from the EMA21 and a negative seasonality.
Sitting on 25% cash at the moment, and patiently waiting before deploying it.
I have a few targets in mind already, with a potential accumulation of my actual assets first, and some speific targets mostly AI hardware stocks - keeping in mind that I own Palantir & Nebius in my own portfolio, bought before the creation of the Savvy. But those two stocks aren’t really hardware, and I want to build more exposure to the sector. Plus some other names I have an interest in. Here’s a short list.
AI Hardware: AsteraLabs, Arista Network, TSM, Nebius & Nvidia.
Uranium: Cameco Corp., Centrus Energy.
Other: MercadoLibre, On Running, Sea Limited.
Those names will be my focus in terms of new positions if given opportunities.
The swing portfolio is back on par with the S&P500, and would be above if Duolingo didn’t give its gains back after earnings due to a silly video from OpenAI.
I have confidence that my system is improving and that I can deliver much better results, with more discipline. The most important lesson being to not overtrade & focus on names I know top to bottom.
Less is more.
This is also true for my options account, which had it tough these last months as I overdid it on a few names and took lots of trades instead of having bigger ones on strong convictions - which worked.
That’s what I started to change the last months, with a big trade on TransMedics - not paying off yet as the stock gave back some gains, but I am holding with confidence, while my second big trade on Venture Global is really red, a perfect illustration of why I should focus on companies I have clear knowledge of, and not those which macro should impact - as VG is down big time despite my thesis of growing LNG demand being 100% right.
So during the next months, expect less trades, but bigger ones on convictions, and expect to see more sold puts.
Transmedics FDA Approval for Heart Trials.
I covered TransMedics results last week, which were really good, and during which management confirmed that they received the FDA approval for their next-gen OCS lungs trial.
A few days later, they also received the approval for their heart trials with a sample siwe of more than 650 patients. Both trials will run during H2-25, as planned.
“As I have stated before, we hope these two trials will be major catalysts for clinical adoption for both heart and lung throughout 2026 and beyond."
Positive feedback would be massive for the company, expanding its TAM & potential, with even more growth verticals to come in the future - international expansion, kidney... Another very positive news.
Novo Nordisk, Hims & Semaglutide.
You guys know that I closed my position on Hims due to a slower business & risks of legal pursuit from Novo. The latter started its legal actions this week against many semaglutide compounders at once, although Hims is not part of the group yet.
Their objective was clear, but they made a communication to make it even clearer.
"Telehealth companies where corporations, not doctors, improperly steer patient care to compounded semaglutide drugs using sham claims of personalization, violating California law."
Once again, Hims is not in the list, but I wouldn’t see this as a given. The company might never be sued by Novo, but the risk remains the same for now.
Weekly Planning.
The next week will be quiet, with only a few companies reporting their quarter.
You’ll receive a detailed review on On Running, Cava & Sea Limited, all three reporting the same day so I will focus on the more important to be released first. And some comments on AST & JD.
Earnings Review.
Closing on a very busy earnings week, here’s a recap of all write-ups. As a reminder, the Hims review details why I closed the position entirely.
